Inventor
LUNDE BRADLEY M
US10 patents
Patents
10 patentsUS11884733B2Jan 30, 2024
Antibody variable domains targeting the NKG2D receptor
DRAGONFLY THERAPEUTICS INC10 citations85
US11939384B1Mar 26, 2024
Antibody variable domains targeting the NKG2D receptor
DRAGONFLY THERAPEUTICS INC9 citations84
US11884732B2Jan 30, 2024
Proteins binding HER2, NKG2D and CD16
DRAGONFLY THERAPEUTICS INC6 citations73
US12384847B2Aug 12, 2025
Cancer therapy involving an anti-PD1 antibody and a multi-specific binding protein that binds NKG2D, CD16, and a tumor-associated antigen
DRAGONFLY THERAPEUTICS INC2 citations72
US12129300B2Oct 29, 2024
Antibody variable domains targeting the NKG2D receptor
DRAGONFLY THERAPEUTICS INC1 citations72
US12275791B2Apr 15, 2025
Multi-specific binding proteins that bind HER2, NKG2D, and CD16, and methods of use
DRAGONFLY THERAPEUTICS INC1 citations62
US12264200B2Apr 1, 2025
Antibody variable domains targeting the NKG2D receptor
DRAGONFLY THERAPEUTICS INC0 citations61
US12215157B2Feb 4, 2025
Multi-specific binding proteins that bind CD33, NKG2D, and CD16, and methods of use
DRAGONFLY THERAPEUTICS INC1 citations61
US12384851B2Aug 12, 2025
Multi-specific binding proteins that bind BCMA, NKG2D and CD16, and methods of use
DRAGONFLY THERAPEUTICS INC1 citations60
US12378318B2Aug 5, 2025
Proteins binding NKG2D, CD16 and a tumor-associated antigen
DRAGONFLY THERAPEUTICS INC1 citations60